<DOC>
	<DOCNO>NCT02644018</DOCNO>
	<brief_summary>The purpose study determine whether Ingavirin ® dose 30 mg daily effective safe treatment influenza acute respiratory viral infection course standard therapy 3-6 year old patient .</brief_summary>
	<brief_title>Efficacy Safety Study Ingavirin® Treat Influenza Other Acute Respiratory Viral Infections Patients 3-6 y.o .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>The informed consent form sign patient 's parent/adoptive parent participate clinical study . Male female patient age 36 . Patients moderate course influenza acute respiratory viral infection . Patients clinically diagnose influenza ARVI base body temperature &gt; 37,5 ° C , less 1 follow symptom intoxication le 1 follow catarrhal symptom : Intoxication symptom : headache , malaise , myalgia , pain eyeball ; Catarrhal symptom : sore throat , rhinorrhea , cough , nasal congestion . Established diagnosis J06.9 , J10 , J11 , accordance ICD10 . Uncomplicated course influenza ARVI . Interval onset symptom enrollment study 36 hour . Complicated course influenza acute respiratory viral infection . Treatment antiviral drug ( antiviral , interferon interferon inducer ) , drug immunomodulatory effect antibiotic systemic local action within 14 day prior screen visit . Severe influenza ARVI symptom cardiovascular disease , symptom infectioustoxic shock , meningoencephalitic syndrome . Signs primary viral pneumonia development ( presence two follow symptom ) : shortness breath , chest pain coughing , systemic cyanosis , dullness percussion sound symmetrical assessment upper low part lung . Infectious disease within last week prior enrollment . `` RRI child '' ( incidence ARVI within last 12 month 6 time ) . Asthma history . History increased seizure activity . Severe decompensated unstable medical psychiatric condition ( disease condition threaten life patient worsen patient 's prognosis also make impossible conduct clinical study patient ) . Cancer , HIV infection , tuberculosis , include history . Hypersensitivity imidazolyl ethanamide pentandioic acid and/or excipients Ingavirin product . Diabetes , lactose intolerance , lactase deficiency , glucosegalactose malabsorption , deficiency sucrase/isomaltase , fructose intolerance , hereditary glucose malabsorption , deficiency glucose6phosphate dehydrogenase . Participation patient clinical trial within last 90 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ingavirin</keyword>
	<keyword>Common Cold</keyword>
	<keyword>Influenza</keyword>
	<keyword>Acute Respiratory Viral Infections</keyword>
	<keyword>pediatric clinical trial</keyword>
	<keyword>Imidazolyl ethanamide pentandioic acid</keyword>
</DOC>